

# INVITATION

# 17 NOVEMBER 2023

# 8th NORDIC PHOTOPHERESIS MEETING

## Helsinki, Finland

This information is intended for healthcare professionals based in Europe and the Middle East

## Agenda

**Time: 09:00 – 16:30**

Moderator **TBC**

09:00 – 09:30 **Registration & Coffee**

### SESSION 1

09:30 – 09:40 **Welcome and introduction**  
**Speaker TBC**

09:40 – 10:25 **Major barriers to progress therapy of Chronic GvHD in 2023 – A new cGvHD “to do list”**  
**Dr. Steven Pavletic**, Center for Cancer Research, NCI, NIH, USA

10:25 – 10:55 **How to measure response in chronic GvHD patients**  
**Dr. Francesca Kinsella**, University of Birmingham, United Kingdom

10:55 – 11:10 **Break**

11:10 – 11:40 **Managing cGvHD with combination therapy**  
**Prof. Zinaida Perić**, University Hospital Center Zagreb, Croatia

11:40 – 12:00 **Q&A Session 1**

12:00 – 13:00 **Lunch**

### SESSION 2

13:00 – 13:30 **ECP & Immunosuppression sparing**  
**Dr. Arun Alfred**, The Rotherham NHS Foundation Trust, United Kingdom

13:30 – 14:00 **Use of ECP in different organs**  
**Dr. Francesca Kinsella**, University of Birmingham, United Kingdom

14:00 – 14:30 **Experience of ECP in gut aGvHD in Helsinki**  
**Dr. Vesa Lindström**, Helsinki University Hospital, Finland

14:30 – 14:45 **Q&A Session 2**

14:45 – 15:00 **Break**

### SESSION 3

15:00 – 15:30 **GvHD patient cases – How would you manage this?**  
**Prof. Zinaida Perić**, University Hospital Center Zagreb, Croatia

15:30 – 16:00 **Survival – How to improve survival in GvHD patients?**  
**Dr. Steven Pavletic**, Center for Cancer Research, NCI, NIH, USA

16:00 – 16:15 **Q&A Session 3**

16:15 – 16:30 **Closing remarks**

*ECP: Extracorporeal Photopheresis, aGvHD: Acute Graft versus Host Disease, GvHD: Graft versus Host Disease, cGvHD: Chronic Graft versus Host Disease*

*All speakers are subject to contract.*

**This is a commercial programme run by Therakos (UK) Ltd, a Mallinckrodt Company.**

Follow the  
Therakos Institute



[Privacy policy](#)

For more information on THERAKOS ECP Immunomodulation™ please visit [www.therakos.eu](http://www.therakos.eu)  
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.  
© 2023 Mallinckrodt. Item code: EU-2300231. Date of preparation: July 2023.

*Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides additional information.*